Semaglutide treatment was found to reduce healthcare costs significantly for patients with overweight or obesity and who had either heart failure or atherosclerotic cardiovascular disease, according to studies presented Nov. 3-6 at the Obesity Society’s annual Obesity Week conference and reviewed Nov. 6 in the American Journal of Managed Care.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
